Blog

Photo from Angelo Pirozzi/X

Jun 9, 2024, 09:31

Angelo Pirozzi: Update on FIGHT-202

Angelo Pirozzi, Research Fellow at Mayo Clinic, shared on X:

“Update on FIGHT-202

145 patients with pretreated advanced CCA and FGFR2 alterations received pemigatinib

Median follow-up 45 mos For FGFR2 fusions:

ORR 37%
mDOR 9.1 mos
mPFS 7.0 mos
mOS 17.5 mos
10.2% TEAEs led to discontinuation.“

Angelo Pirozzi

Read further.
Source: Angelo Pirozzi/X

Angelo Pirozzi cancer FGFR2 Alterations FIGHT-202 OncoDaily Oncology

Carlos Rodriguez-Galindo: The Man Who Will Cure the World

Esophageal Cancer: Symptoms, Causes, Stages, Diagnosis & Treatment

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Special Coverage

ESMO 2024 Congress
September 13-17, 2024
ASCO Annual Meeting
May 30 - June 4, 2024
Yvonne Award 2024
May 31, 2024
OncoThon 2024, Online
Feb. 15, 2024
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023

Facebook

RSS Feed

Youtube

Science

Dec 22, 2024, 10:15

Dégi László Csaba: Thrilled to announce the new Lancet Oncology Policy Review analyzing NCCPs worldwide

Science

Dec 22, 2024, 10:13

Denis Horgan: Delayed Access to Personalized Medicine in the EU - What’s the Cost to Patients?

Blog

Dec 22, 2024, 10:12

Emad Shash: Honor to be among the newly elected council of the Egyptian Cancer Society

Science

Dec 22, 2024, 10:03

María Natalia Gandur Quiroga: Checkpoint inhibitors and Fc functions - key findings in oncology immunotherapy

Science

Dec 22, 2024, 10:00

Francesco Maura: CD38 loss as mechanisms of resistance to anti-CD38 MoAb in myeloma

Science

Dec 22, 2024, 09:59

CDK4/6 inhibitors: mechanisms of resistance and where to find them - Lorenzo Gerratana

Blog

Dec 22, 2024, 09:53

India's Oncology Testing Market Projected to Grow at 2% CAGR Through 2033: GlobalData

Dialogues

Dec 22, 2024, 09:40

Botensilimab: A Novel Anti-CTLA- 4 Therapy Effectively Treats Refractory Colorectal Cancers

Dialogues

Dec 22, 2024, 09:04

Carlos Rodriguez-Galindo: The Man Who Will Cure the World

Science

Dec 22, 2024, 08:16

Essential Requirements for Quality Cancer Care: Ovarian - European Cancer Organisation

Science

Dec 22, 2024, 08:13

Liang Cheng: Advancements in biomarkers and molecular diagnostics in HR+ Breast Cancer

Science

Dec 22, 2024, 07:59

Ilana Schlam: The BRIDGES study is out